Rapivab
Rapivab Uses, Dosage, Side Effects, Food Interaction and all others data.
Rapivab is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. Being an influenza virus neuraminidase inhibitor, peramivir works by preventing new viruses from emerging from infected cells. Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company. The injectable intravenous formulation of peramivir was approved by the FDA in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic for no more than two days.
Trade Name | Rapivab |
Availability | Prescription only |
Generic | Peramivir |
Peramivir Other Names | Peramivir |
Related Drugs | amantadine, Tamiflu, oseltamivir, Vicks DayQuil Severe Cold & Flu, Xofluza, Coricidin HBP Cold & Flu |
Weight | 10mg/ml, |
Type | Intravenous solution |
Formula | C15H28N4O4 |
Weight | Average: 328.4072 Monoisotopic: 328.211055404 |
Groups | Approved, Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | United States, |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Rapivab is an intravenous antiviral agent used to treat acute uncomplicated influenza in patients aged 2 years and older who are shown to be symptomatic for no more than two days.
Indicated for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days.
Rapivab is also used to associated treatment for these conditions: Acute, uncomplicated Influenza
How Rapivab works
Rapivab is an inhibitor of influenza neuraminidase, preventing new virus particles from leaving infected cells.
Food Interaction
No interactions found.Rapivab Disease Interaction
Innovators Monograph
You find simplified version here Rapivab